In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpineVision: Meeting the Competition Head On

Executive Summary

Spine surgery has gone from the pariah of the orthopedic industry to that sector's fastest growing segment. Large companies have looked to capitalize on spine's rapid growth by acquiring their way into this space, a pattern of consolidation that has left the industry without a major pure play spinal company. SpineVision is looking to fill that void by developing a complete line of spinal products, starting with innovations on core technology, rather than relying on a typical start-up strategy of focusing on a particular device or clinical niche. The company's strategy will bring it immediately into competition with the market leaders' well-established product lines. But SpineVision is counting on experienced management and the current frustration among spine surgeons resulting from recent industry consolidation to attract physicians' attention.

You may also be interested in...



SpineGuard: Taming Of The Screw

Much of the innovation in spine over the past decade has aimed at replacing fusion, the standard of care. SpineGuard’s novel sensor technology is betting on fusion’s long-term prospects, helping patients and surgeons by making the procedure safer.

Spine Update: BMP Use Continues to Expand

Medtronic recently declared that InFUSE, the company's blockbuster spine bone graft product that provides the growth factor rhBMP-2 as part of a lumbar fusion cage, was well on its way to becoming standard of care in spine surgery. The company's success has fueled interest in a plethora of potential entrants into the biologic bone formation market.

Sofinnova's Window on Early-Stage Technology in Europe

In Europe, one of the historical obstacles to company creation has been a lack of venture capital funding. Not any longer. Abingworth's life-science-focused fund, Abingworth Bioventures IV, raised $350 million; Schroder Ventures Life Sciences' fund International Life Sciences III was $402 million; and the latest life sciences fund of Techno Venture Management was $450 million. These funds now rival their counterparts on the East Coast or the Bay area of the US. Now, the Paris-based venture capital firm Sofinnova Partners has closed its fifth fund, at €385 million ($516 million). Sofinnova Capital V is perhaps the largest European fund dedicated to early-stage investing in life sciences and IT, with a focus on European companies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel